Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.
about
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repressionEpimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesEpigenetic regulators and their impact on therapy in acute myeloid leukemiaEvolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative NeoplasmsCytogenetic and molecular abnormalities in chronic myelomonocytic leukemiaGenetics of myeloproliferative neoplasmsRevisiting the case for genetically engineered mouse models in human myelodysplastic syndrome researchHistone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and preventionASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutationsA novel BCR-ABL1 fusion gene with genetic heterogeneity indicates a good prognosis in a chronic myeloid leukemia case.Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of ThroMayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phaseFrequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical ApproachCurrent outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing.Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapyEZH2 as a potential target in cancer therapy.Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean PopulationImpact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemiaTetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.Digging deep into "dirty" drugs - modulation of the methylation machinery.Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemiaMutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia.Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AMLMolecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblastsPerspectives and future directions for epigenetics in hematology.The future of epigenetic therapy in solid tumours--lessons from the past.Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2aEpigenetic changes: a common theme in acute myelogenous leukemogenesisClinical and biological implications of driver mutations in myelodysplastic syndromes.Epigenetics of hematopoiesis and hematological malignancies.Loss of the tumor suppressor BAP1 causes myeloid transformation.
P2860
Q24296658-5B3B82B5-4E71-4FE6-8A6B-2539D8ABA176Q26744080-422D96A2-CC9E-4510-A2A3-E38A41D3664EQ26765402-2FE46A2F-3112-4BE9-BBAC-20CD855262BBQ26766319-41585F5A-386D-4A03-BB9D-6093D420E14DQ26768600-7520C2E7-11B2-4D2B-9F7E-09DD5CE4FA34Q26823651-1EC8B264-63E1-411A-9A40-891F600486ACQ26859843-04289B62-50BD-4546-865E-3B183A5AC44CQ26994739-12FC116B-0098-4B40-A52D-10B3727DB058Q27851679-4513912F-53B6-48E5-A6ED-1CF0840300AEQ27851909-227D39BF-5847-4562-A8B8-18E0EF465054Q28590040-43B35E30-56A0-4C07-B7BB-2E48A07515AAQ30152631-000C1173-6798-4C87-B63B-4B4DD11246A0Q30315531-4D303B56-50D6-419C-9F85-11355F48A96BQ33406648-58DB6182-D607-47B0-B201-209FD270CEDFQ33421772-E2929B14-57C1-4346-B54C-FA7A9405534EQ33558154-47B12FA5-41E3-4816-9E9D-17BFC8381E17Q33701852-00057966-E3AF-4E73-958A-9FCC2C31F7A5Q33888064-9FC51472-EF93-4A02-BECC-6F994510C165Q34302770-47391DC6-9D3D-4E40-A0FF-D6F2F7C1B255Q34348505-7A6EB05C-EFDA-4D85-9000-7A756072B834Q35132953-4150DD93-52C5-43A3-BA48-387195F87B16Q35222823-CA36E89B-7284-451E-BBAA-44C592C468AEQ35332017-0EB99533-5573-46DD-87BF-EE3CCAE51F26Q35654081-BAB00DB2-6174-47B2-96B9-70F0D50A79F6Q35669864-8D034CBE-A3A3-4E8E-B732-60273C207E12Q36001930-38ECABB2-87E3-40BF-B4C3-5C4FD8D23B23Q36267848-282C0A60-F142-4921-BA22-5938BB4A4A77Q36366973-F45EF84A-87EA-40CD-852E-25B25E55E6D0Q36523796-D745A42D-B31A-4CF7-B7D0-B04105520009Q36548070-EEB126F8-455C-41AD-8451-C4CC4F9C8830Q36583644-B5F1E0AC-081C-4C3E-890E-0F7D9C20052EQ36797201-A0BC0C2B-46D2-4F88-9A2D-1CF4DBEF0360Q36936451-6621DB9E-6EED-49B1-8946-27017896D140Q36962664-D3746DBB-B5DD-4E63-83FB-6D332B4D071FQ37061554-BB4DEE0A-B0A0-4728-BFE7-FA14E23EA5CEQ37083947-F9432591-F17E-4927-B0ED-0327C50F5A58Q37116613-7B7B56C4-B539-4647-9D74-BC95D228BB29Q37334716-3AEE5142-0733-4366-A6F5-3F7FB2C9806DQ37343797-4703CE31-BA2A-4217-B141-E5F0FF2464B2Q37545704-E26957B8-3CCC-40B8-B0F2-A665FF76AEB2
P2860
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Concomitant analysis of EZH2 a ...... myeloproliferative neoplasms.
@ast
Concomitant analysis of EZH2 a ...... myeloproliferative neoplasms.
@en
type
label
Concomitant analysis of EZH2 a ...... myeloproliferative neoplasms.
@ast
Concomitant analysis of EZH2 a ...... myeloproliferative neoplasms.
@en
prefLabel
Concomitant analysis of EZH2 a ...... myeloproliferative neoplasms.
@ast
Concomitant analysis of EZH2 a ...... myeloproliferative neoplasms.
@en
P2093
P2860
P356
P1433
P1476
Concomitant analysis of EZH2 a ...... myeloproliferative neoplasms.
@en
P2093
A Pardanani
D G Gilliland
M Wadleigh
O Abdel-Wahab
R L Levine
P2860
P2888
P304
P356
10.1038/LEU.2011.58
P577
2011-04-01T00:00:00Z